As­traZeneca, Dai­ichi Sankyo claim PhI­II lung can­cer win for their next big ADC — but shares fall

As­traZeneca and Dai­ichi Sankyo’s multi­bil­lion-dol­lar an­ti­body-drug con­ju­gate al­liance has gen­er­at­ed a Phase III win, the part­ners say, beef­ing up the case that they have a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER